on behalf of the PHAROS Investigators BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH.
Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, immune dysregulation, and fibrosis of the skin and internal organs. Right heart catheterization (RHC) confirmed pulmonary arterial hypertension (PAH) affects 8% to 12% of patients with SSc, is a leading cause of death, and is an independent predictor of early mortality. [1] [2] [3] [4] The SSc standardized mortality ratio (observed to expected mortality) increases from 3.4 to 4.1 to 5.8 in patients with PAH. [4] [5] [6] When compared with patients with idiopathic or other connective tissue disease-associated PAH, patients with SSc-PAH have higher mortality rates despite similar or less severe baseline hemodynamics [7] [8] [9] [10] ; however, there is emerging evidence that treatment results in improved outcomes. 6, [11] [12] [13] [14] [15] Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) is a multicenter registry designed to prospectively follow patients with SSc at high risk for or with incident pulmonary hypertension (PH). 16 Patients enrolled in PHAROS are from institutions that actively screen their patients for PAH. The 1-and 3-year survival rates are 93% and 75% in this cohort, which is superior to other cohorts. 7, 8, 10, [17] [18] [19] [20] [21] [22] [23] Predictors of mortality in the short term in patients with SSc-PAH from the PHAROS registry include being males, older age, New York Heart Association (NYHA) functional class IV, and low diffusing capacity of carbon monoxide (DLCO) at the time of diagnosis. 17 Analysis of data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), another large multicenter PH registry, evaluated unique predictors of mortality and outcomes with follow-up through 5 years after diagnosis in a subset of patients with SSc-PAH. 24, 25 Long-term outcomes and predictors of mortality (>5 years) have not been thoroughly described in the incident SSc-PAH population, however.
The goal of the present study was to assess long-term outcomes and predictors of mortality in an incident SSc-PAH population followed at SSc centers throughout the United States.
Methods
PHAROS is a prospective registry of patients with SSc at high risk for PAH (at risk) or with RHC-diagnosed PH. Details of the registry have been described. 16 Nineteen centers participated and obtained institutional review board approval (e- Table 1 ). Before enrollment, all patients provided written informed consent. Patients were recruited and followed from 2006 through 2016.
There were two patient populations enrolled in the registry: patients with SSc at risk for PAH and those with incident PH. At-risk patient enrollment criteria were: (1) DLCO < 55% predicted with an FVC of > 70% predicted; (2) FVC/DLCO ratio > 1.6; or (3) estimated right ventricular systolic pressure $ 40 mm Hg on ECG. At-risk patients underwent PAH screening annually, or sooner if clinically indicated. RHC was performed for at-risk patients made on the basis of clinical indication during follow-up. Patients with incident PH were diagnosed by RHC within 6 months of enrollment.
The goal of this study was to assess long-term outcomes and predictors of mortality in the subset of PHAROS patients with incident World Health Organization group I PAH. Patients who received diagnoses of incident PAH within 6 months of enrollment or during follow-up (in at-risk group) were included in this study. Incident PAH was defined as mean pulmonary arterial pressure (mPAP) $ 25 mm Hg at rest and pulmonary arterial wedge pressure #15 mm Hg on RHC and FVC $ 65%. If a baseline highresolution CT (HRCT) scan was available, there could be no more than mild fibrosis present.
Baseline clinical and demographic characteristics were assessed at the time of PAH diagnosis. Outcomes evaluated were death (all cause and PAH related), cause of death, and time to clinical worsening (TTCW), which was defined as time to death, PAH-related hospitalization, lung transplantation, initiation of parenteral prostacyclin, and/or worsening symptoms (decrease of > 15% in the 6-min walking distance (6MWD) test and worsening of functional class and addition of PAH-specific medication). 11 The treating physician determined attribution of hospitalization and death.
Cause of death in the short (< 4 years) and long ($ 4 years) term and initial therapy were assessed. Initial therapy was defined as first PAHspecific treatment maintained for at least 3 months with at least 6 months of follow-up. Therapy was categorized as endothelin receptor antagonist monotherapy, phosphodiesterase-5 inhibitor monotherapy, oral combination therapy, and parenteral prostacyclin with or without oral therapy. To address confounding by indication, clinical features were compared between those included and excluded in the analysis as well as between different medication subgroups.
Statistical Analyses
Baseline characteristics were compared between patients who died of PAH-related causes in < 4 years vs survived $ 4 years from diagnosis, and between initial therapy subgroups. Student t test or Wilcoxon rank sum tests were used to compare continuous variables. c 2 or Fisher exact tests were used to compare categorical variables. Kaplan-Meier survival curves were generated for the overall cohort and restricted to PAH-related deaths, clinical worsening, and patient groups stratified by initial therapy from the time of diagnosis. Additional sensitivity analyses assessed survival and TTCW in the following groups: patients with mild vs no fibrosis; excluding patients with left ventricular ejection fraction < 55%; and excluding patients with only mild elevation in pulmonary vascular resistance (PVR) defined as < 3 WU. The latter analysis was performed because PVR was included in the diagnostic criteria for PAH after the PHAROS protocol was developed. 26 Differences in survival were assessed by log-rank test. Cox proportional hazard models were applied to identify predictors of overall survival and clinical worsening. To adjust for missing values, multiple imputation was performed. Discriminant function was applied to impute categorical variables and regression was used to impute continuous variables. Forty imputed datasets were generated. Univariate analyses were performed, followed by multivariate analyses for the imputed datasets; the pooled results were retained. All tests were two-sided and P values < .05 were considered significant. Analyses were performed using SAS 9.4.
Results

Patient Population
One hundred sixty patients with incident SSc-PAH were included. Detailed baseline demographic and clinical characteristics are shown in Table 1 . At diagnosis, the majority of patients were NYHA class I or II (16% and 44%, respectively). Median 6MWD was 366 m, and median hemodynamic values were: mPAP,35 mm Hg; PVR, 4.8 WU; and cardiac output of 5 L/min. Eighty-four patients had an HRCT scan, with 32 patients having mild fibrosis.
Long-Term Outcomes
Fifty-six patients died during a median follow-up time of 7.1 years. The 1-, 3-, 5-, and 8-year cumulative survival rates were 95%, 75%, 63%, and 49%, respectively (Fig 1) , with 52% of deaths related to PAH. The majority of deaths in the short term (<4 years) were due to PAH (61%), whereas 17% of deaths were related to PAH in the long term ($4 years). Cause of death was more often attributable to SSc in the short term, because the long term was equally distributed between SSc-related and SScunrelated causes (Table 2) . When events were restricted to PAH-related deaths, the 1-and 3-year survival rates were 97% and 83%, and 76% at 5 and 8 years after diagnosis (Fig 1) . Compared with long-term survivors, patients who died of PAH-related causes in the short term had significantly shorter 6MWD (P ¼ .022), lower percentpredicted DLCO (P ¼ .009), higher FVC/DLCO (P ¼ .008), and higher systolic pulmonary artery pressure (PAP) on ECG (P ¼ .0001) at the time of diagnosis. They had worse baseline hemodynamics on RHC with higher mPAP (P ¼ .0003) and PVR (P ¼ .0001) and lower cardiac output (P ¼ .04) ( Table 3) . Eighty patients worsened clinically during follow-up. At 1, 3, 5, and 8 years, 24%, 42%, 58%, and 70%, respectively, met criteria for clinical worsening (e- Fig 1) .
There was no significant difference in survival or TTCW when comparing patients with mild vs no fibrosis (P ¼ .923 and P ¼ .462, respectively). For patients with left ventricular ejection fraction $ 55% (n ¼ 119), the 1-, 3-, 5-, and 8-year survival rates were 94%, 79%, 66%, and 50%, respectively, and 23%, 41%, 56%, and 70% worsened during those years. Twelve patients had an ejection fraction < 55% (median, 51%; range, 42%-54%) and 29 had no baseline ejection fraction. For patients with PVR $ 3 (n ¼ 130), the survival rate at 1, 3, 5, and 8 years was 94%, 73%, 58%, and 42%, respectively, and 29%, 46%, 62%, and 75% worsened during those years.
Predictors of Outcomes
Univariate regression analysis assessed predictors of long-term outcomes (Table 4) . On multivariate analysis, men (hazard ration [HR], 3.11; 95% CI, 1.38-6.98), diffuse disease (HR, 2.12; 95% CI, 1.13-3.93), and baseline systolic PAP on ECG (HR, 1.06; 95% CI, 1.01-1.11, for every 3-mm Hg increase), mPAP on RHC (HR, 1.03; 95% CI, 1.001-1.07, for every 1-mg Hg increase), 6MWD (HR, 0.92; 95% CI, 0.86-0.98, for every 10-m increase), and percent-predicted DLCO (HR, 0.65; 95% CI, 0.46-0.92, for every 15% increase) significantly affected survival. Baseline elevated PVR on RHC (HR, 1.11; 95% CI, 1.07-1.16) and decreased percentpredicted DLCO (HR, 0.76; 95% CI, 0.58-0.98) were predictors of clinical worsening by multivariate analysis ( Table 4) .
Effect of Initial Therapy on Survival
One hundred twenty-nine patients met criteria for the medication analyses. Phosphodiesterase-5 inhibitor monotherapy was most common (57%). e- Table 2 describes reasons for exclusion from analysis. The breakdown of initial therapy subgroups by duration of survival is illustrated in Table 5 . Patients started on initial oral (single or combination) therapy had better survival compared with those started on parenteral prostacyclin as monotherapy or in combination (P < .0001) (Fig 2) . The oral combination group did not experience better survival compared with oral monotherapy as has previously been described; however, the combination therapy group was small (n ¼ 12). 12 Anticentromere antibody (ACA) status was significantly different between the initial therapy subgroups (P ¼ .04), with the majority of patients in the systemic prostacyclin and oral combination groups being ACAþ (e- Table 3 ). Patients excluded from the medication analyses had slightly higher PAWP and lower mPAP on RHC (P ¼ .01 and P ¼ .04, respectively), but there was no difference in survival (P ¼ .94).
Discussion
Our study describes long-term outcomes from a large US multicenter prospective cohort of RHC-diagnosed patients with SSc-PAH. These results demonstrate higher survival rates compared with other cohorts. 6, 10, 18, 25 The majority of early deaths (within 4 years after PAH diagnosis) were attributable to PAH, whereas long-term survivors primarily died of non-PAH-related causes. Clinical markers associated with poor outcomes included men, diffuse disease, elevated systolic PAP and mPAP, and lower exercise capacity and DLCO.
Earlier analysis of the PHAROS cohort found predictors of mortality in the short-term included age > 60, men, NYHA functional class IV, and DLCO < 39% predicted. With further follow-up, only DLCO and men remained independent predictors of death. An additional 29 patients were included in our current analysis and patients were followed for a longer period; these factors may account for differences in identified predictors of mortality.
Few studies have assessed long-term survival in incident RHC-diagnosed patients with SSc-PAH. The REVEAL chestjournal.org registry evaluated outcomes through 5 years in newly diagnosed and previously diagnosed PH cases. Patients with SSc-PAH who were newly diagnosed had a 5-year survival rate of 40%, substantially worse than the PHAROS population. 25 There was a higher percentage of patients with functional class III/IV in the newly diagnosed REVEAL SSc-PAH group compared with PHAROS (69% vs 41%). 24 A single-center cohort found a 5-year survival rate of 51% after diagnosis in their SSc-PAH population. 22 Neither patient population was reported to undergo routine surveillance for PAH before diagnosis. A small study of patients undergoing screening for PAH compared with those diagnosed during routine clinical practice found significantly better survival of the former group (64% vs 17%) at 8 years.
14 Our study substantiates the potential effect of screening on long-term survival in patients with SSc-PAH in a large multicenter cohort; however, further research is needed to definitively show screening results in early diagnosis and/or improves survival.
Though difficult to make direct comparisons to other cohorts, it is notable that the majority of PHAROS patients were classified as functional class I/II, whereas the majority of patients in cohorts with worse survival were functional class III/IV at the time of enrollment. 6, 10, 18, 25 Prior studies have identified functional class as an important predictor of survival. 20, 22, 25, 27 The recent Australian cohort used annual ECG and pulmonary function tests to screen for patients at high-risk for PAH. Criteria for referral Cardiac output, L/min (160) 4 (2-7.7) 5.2 (1.5-9.5) .042
Data are presented as No. (%) unless otherwise indicated. RHC ¼ right heart catheterization. Bold P value indicates significant (< .05). See Table 1 legend for expansion of other abbreviations.
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to RHC was more stringent in that study, with referral occurring if systolic PAP was at least 50 mm Hg and/ or DLCO < 50% predicted with FVC > 85% predicted. 6 This cohort had worse baseline functional status and survival at 3 years (62%). Better functional status and survival in PHAROS could reflect active surveillance and earlier diagnosis 14 ; however, early diagnosis and higher survival rates may be partially attributed to lead time bias. Additionally, it is not known if better functional class equates with earlier disease.
Our results suggest that a subset of patients with PAH die of PAH-related causes within the first years after diagnosis. Our findings are consistent with other studies showing that patients with incident PAH have poorer survival rates than those with prevalent disease. 25 Not unexpectedly, patients who died in the short term had more severe disease at baseline with shorter 6MWD, lower percent-predicted DLCO, higher FVC/DLCO, higher systolic PAP, and worse hemodynamics on RHC. It is possible that other cohorts with worse outcomes may have been enriched with patients with more severe disease. Our study showed that patients initiated on a parenteral prostacyclin had poorer survival, likely reflecting a more severe disease state at baseline and confounding by indication. 28 Although there was a trend toward worse functional status and higher mPAP in the prostacyclin group, however, the only significant difference in baseline clinical characteristics between the different initial therapy groups was ACA status. Another explanation for these findings is that prostacyclins may not be as efficacious in this population.
The major limitation of our study is that it is observational in nature, and therefore missing data were unavoidable; however, all patients included in this analysis were required to have an RHC for diagnosis. An additional limitation of this study is the inability to validate that only an incident PAH population was included. Although many patients were being followed at centers that screen for PAH as part of routine clinical practice, it is possible that cases of prevalent rather than incident PAH were included and at-risk patients with true PAH were missed given limitations of current screening methods. In addition, although we attempted to include only patients with PAH using RHC hemodynamics, pulmonary function test, and HRCT data, it is possible that some patients with PH related to left heart disease or interstitial lung disease may have been included. PVR was not an inclusion criterion for the incident PAH group. However, outcomes did not change significantly when those with PVR < 3 WU were excluded. The small number of patients in each therapeutic subgroup, few events, and lack of randomization limited our analysis of the effect of treatment on mortality. Furthermore, we were unable to assess the effect of anticoagulation or therapies added or substituted during follow-up because of missing data.
Finally, it is difficult to account for changes in treatment Table 2 for definition of other abbreviations.
chestjournal.org practices over time considering the rapid evolution in therapy options over the past 15 years. 29 
Conclusions
Our study assessed long-term outcomes and identified predictors of survival in patients with incident SSc-PAH. Baseline clinical features that can help risk-stratify these patients include men, diffuse disease, systolic PAP on ECG, mPAP on RHC, 6MWD, and DLCO. Approximately one-half of deaths were PAH-related and primarily occurred in the first years after diagnosis. Further research is needed to identify early markers and optimal treatment strategies for patients with SSc who have high early PAH-related mortality.
